Steatotic liver disease: a dynamic spectrum, not a static state

Abstract

Steatotic liver disease (SLD) is a growing global health threat affecting more than 1 in 3 individuals and encompasses the spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD) (Figure 1).¹ MASLD, MetALD and ALD are driven by the rising prevalence of type 2 diabetes (T2M) and obesity and increased alcohol consumption has led to a rising incidence of liver cirrhosis and hepatocellular cancer. SLD is now the leading indication for liver transplantation in many regions globally.²